Participants with mild-to-moderate COVID-19 are being sought for the ACTIV-6 study, which is evaluating the medication as one of three repurposed medicines. medications that the FDA has previously cleared for usage in other medical situations are known as repurposed medications.

"Data from modeling studies, published clinical research, and community interest support investigating multiple doses and durations of ivermectin," said Adrian Hernandez, M.D., the study's administrative principal investigator and executive director of the DCRI. "This expansion will provide valuable information about how ivermectin works and whether it can help people with mild-to-moderate COVID-19 symptoms stop their illness from getting worse for Ivermectin 12 Mg.."

The extended study medication arm is given a daily dose of 600 mcg/kg for six days. Ivermectin, a drug used to treat parasitic infections, has not been authorized by the FDA to treat COVID-19. It should only be utilized as an ACTIV-6 research trial participant.

Due to the positive outcomes of using Ivermectin 12 Mg, enrollment in the arm trial has been closed. The patient was given 400 mcg/kg of ivermectin every day for three days. The treatment arms that are now accepting enrollment are listed on the ACTIV-6 website, and more arms will soon be added to the ACTIV-6 testing platform.

ACTIV-6, also known as "The Randomized Trial to Evaluate Efficacy of Repurposed Medications," is a double-blind, nationwide study that has attracted over 3,000 participants thus far. It is expected that enrollment will.

To be eligible for the trial, participants must be 30 years old or older, have a positive COVID-19 test within the last 10 days, and have had at least two symptoms of the illness for no more than seven days. To join, potential volunteers can indicate their interest in the study by calling 833-385-1880 or filling out the online survey on the study's website.

Participants can come from anywhere in the United States, and there is no cost for the free distribution of medications to their homes. There is no need to visit or get treated at the research clinic. To participate, you must take the medicine and document your symptoms for ninety days by completing out surveys on the phone. 

Susanna Naggie, M.D., the DCRI principal investigator in charge of the study's clinical coordinating center, stated, "We have treatments for people with mild-to-moderate COVID-19 who are at high risk for hospitalization or death, but they remain in limited supply, and each current authorized drug has limitations." "We need more medications that can be taken at home to treat the symptoms of the virus to help people feel better faster, especially as cases of the Omicron variant surge nationally, straining health systems and medical personnel."

Naggie stated that additional medications will be introduced to the trial over time. The medications chosen for ACTIV-6 research have indicated promise in treating COVID-19 in the outpatient context; nevertheless, more testing in a more thorough, careful, and randomized clinical trial.